About a dozen activists from the Extinction Rebellion climate group briefly occupied the entrance lobby of French bank BNP ...

The obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk NVO and Eli Lilly LLY, respectively. This ...

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

With political action underway through an executive order from President Donald Trump and pharmaceutical industry shifts emerging, the question remains whether these changes will lead to sustained ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

Employers have the opportunity to lead by example: to stop treating obesity as invisible and start addressing it as the ...

Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently ...

The Trump administration released a 72-page report Thursday outlining its take on what's driving "a chronic disease crisis" ...